Bastien Izzo

BrainEver is a biopharmaceutical company developing a pipeline of novel therapies for patients with age-related neurodegenerative diseases, such as Charcot disease, Parkinson’s, and glaucoma, the second leading cause of blindness. Our mission is to develop recombinant human Homeoproteins (HPs) to halt disease progression by stopping neuronal loss and durably restoring the physiology and metabolism of the remaining neurons. BrainEver was co-founded by Bernard Gilly (iBionext) and Alain Prochiantz (Collège de France). Our innovative therapeutic approach stems from the pioneering work of Alain Prochiantz and his team on brain development and physiology. Our lead project, BREN02, focuses on developing recombinant human Engrailed-1 (hEN1) for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS). Building on the highly promising results of our preclinical studies, we are preparing to launch clinical trials by 2025. Follow us!

Nodale turns your product into personalized demo videos, automatically. Video wins B2B deals today: buyers watch a demo before they buy, and reps who send video close more. But recording a tailored demo for every prospect costs a rep weeks each year, so most never get made. Nodales AI agents explore your SaaS on their own and generate a personalized demo video for each prospect, ready to send by your AEs, CS, and Marketing teams. The demo your buyer actually needs, without the work your team doesnt have time for. We call it the Agentic GTM Demo Engine.

A network for entrepreneurs building in stealth. Submit your information here so investors can find you: harmonic.ai/get-discovered

Were hiring worldwide! https://wandercraft.welcomekit.co/ At Wandercraft, we believe movement is freedom. Since 2012, our mission has been simple but bold: restore mobility where it’s been lost, and expand what’s possible with robotics that move like people do. We see robotics as the ultimate partners—machines that can do what humans cannot, or should not, do. That means giving back the ability to walk to someone with a spinal cord injury, or stepping in on a factory floor where work is too heavy, repetitive, or hazardous. We pioneered the world’s first self-balancing exoskeleton—technology that doesn’t rely on crutches or walkers, but lets people stand and walk freely. Today, our work goes beyond healthcare. From rehabilitation centers to factory floors, and soon into homes and communities, we’re shaping a future where humans and robots move forward together. Our technology, powered by physical AI and 30+ patents, is life-tested in the most demanding environments: real people, real steps, real work. Meet our devices: Atalante X – A self-balancing exoskeleton enabling hundreds of patients with mobility disabilities to take over 1 million steps per month in 100+ leading hospitals and research centers worldwide. It is designed to promote upright posture, cardiovascular health, neuroplasticity, and—most importantly—upright independence. Eve – The world’s first self-balancing exoskeleton for personal use. Designed for daily life, Eve enables individuals with severe mobility impairments to walk hands-free at home and outdoors. Currently in U.S. clinical trials, Eve is expected to launch in 2026. Calvin-40 – Our first industrial humanoid robot. Autonomous and voice-operated, Calvin-40 is built to take on physically demanding or hazardous tasks in non-ergonomic environments. Based on the same platform as our exoskeletons, Calvin is already hard at work with Renault Group and more.

BrainEver is a biopharmaceutical company developing a pipeline of novel therapies for patients with age-related neurodegenerative diseases, such as Charcot disease, Parkinson’s, and glaucoma, the second leading cause of blindness. Our mission is to develop recombinant human Homeoproteins (HPs) to halt disease progression by stopping neuronal loss and durably restoring the physiology and metabolism of the remaining neurons. BrainEver was co-founded by Bernard Gilly (iBionext) and Alain Prochiantz (Collège de France). Our innovative therapeutic approach stems from the pioneering work of Alain Prochiantz and his team on brain development and physiology. Our lead project, BREN02, focuses on developing recombinant human Engrailed-1 (hEN1) for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS). Building on the highly promising results of our preclinical studies, we are preparing to launch clinical trials by 2025. Follow us!

LA plateforme de recrutement qui aide les entreprises à trouver LA bonne personne grâce à la culture dentreprise.